Hospital Quironsalud Barcelona
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The Instituto de Oncología de Barcelona includes a strong program in cardiovascular disease, evaluating new therapies to lower heart‑related events and improve blood pressure control.
- Atherosclerotic cardiovascular disease
- Heart failure
- Hypertension
- High cardiovascular risk
- Established cardiovascular disease
With more than 120 active trials and 59 investigators, Hospital Quironsalud Barcelona is advancing preventive and treatment strategies for heart conditions.
Digestive System Diseases
Research at the site targets digestive system diseases, focusing on innovative treatments for gastrointestinal cancers and related disorders.
- Colorectal cancer
- Gastric cancer
- Esophageal cancer
- Pancreatic ductal adenocarcinoma
- Non‑muscle invasive bladder cancer
Trials explore targeted agents, immunotherapies, and combination regimens to increase survival and quality of life for patients with digestive tract malignancies.
Hemic and Lymphatic Diseases
The centre conducts studies in hemic and lymphatic diseases, aiming to improve outcomes for blood‑related cancers and disorders.
- Diffuse large B‑cell lymphoma
- Follicular lymphoma
- Other hematologic malignancies
- Chronic lymphocytic leukemia (investigational)
- Myeloma (early‑phase studies)
By testing novel antibodies and cellular therapies, investigators seek to enhance remission rates and reduce treatment toxicity.
Immune System Diseases
A dedicated effort focuses on immune system diseases, including autoimmune conditions and immune‑modulating cancer therapies.
- Rheumatoid arthritis
- Immune checkpoint inhibitor combinations
- Autoimmune adverse event management
- Inflammatory biomarkers research
- Immunotherapy safety profiling
The program evaluates how modulating immune pathways can both treat malignancies and alleviate autoimmune disease activity.
Neoplasms
The primary focus of the institute is on neoplasms, conducting extensive trials across a wide spectrum of solid tumors.
- Breast cancer (including HER2‑positive, triple‑negative, HR+)
- Non‑small cell lung cancer
- Prostate cancer
- Ovarian cancer
- Bladder cancer
- Melanoma
- Head and neck squamous cell carcinoma
- Gastric and gastro‑oesophageal junction adenocarcinoma
- Pancreatic cancer
- Renal cell carcinoma
Trials range from early‑phase safety studies to late‑stage efficacy assessments, seeking better response rates, longer survival, and improved quality of life.
Nutritional and Metabolic Diseases
Studies in nutritional and metabolic diseases address metabolic syndrome, lipid disorders, and diabetes‑related complications.
- Hypertriglyceridemia (severe and moderate)
- Obesity
- Type 2 diabetes mellitus
- Chronic kidney disease with metabolic involvement
- Lipid metabolism modulation
By testing agents such as inclisiran, finerenone, and empagliflozin, investigators aim to reduce cardiovascular events and renal decline.
Respiratory Tract Diseases
The site includes research on respiratory tract diseases, combining oncology and infectious disease approaches.
- Non‑small cell lung cancer
- Small cell lung cancer
- Respiratory syncytial virus infection
- Influenza immunisation
- Bronchial inflammation studies
Clinical trials evaluate novel immunotherapies, antiviral vaccines, and supportive care strategies to improve lung health.
Virus Diseases
Research in virus diseases focuses on prevention and treatment of viral infections affecting vulnerable populations.
- Influenza vaccination efficacy
- Respiratory syncytial virus (RSV) therapeutics
- Human metapneumovirus studies
- Virus‑associated cancer immunotherapy
- COVID‑19 follow‑up investigations (observational)
The program seeks to enhance immunity, reduce disease severity, and explore viral antigens as targets for cancer treatment.
Metabolism
Investigations of metabolism explore biochemical pathways that influence disease progression and treatment response.
- Lipid metabolism and atherosclerotic risk
- Albumin‑creatinine ratio in chronic kidney disease
- Metabolic profiling of tumor microenvironment
- Glucose homeostasis in diabetic patients
- Energy balance in cancer cachexia
By linking metabolic biomarkers to therapeutic outcomes, researchers aim to personalize interventions across multiple disease areas.
Physiological Processes
The institute also studies fundamental physiological processes that underlie health and disease.
- Cardiovascular homeostasis
- Immune system regulation
- Cellular signaling in tumor growth
- Renal filtration dynamics
- Respiratory gas exchange efficiency
Understanding these processes supports the development of therapies that restore normal function and improve patient outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 12 therapeutic areas and 15 of 165 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 158 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 58 by active trials.
- 1Novartis Pharma AG3active
lock +57 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG6trials
lock +28 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Quironsalud Barcelona
lock Showing 1 of 150 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Comparative Study of ABP 234 and Pembrolizumab in Patients with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Amgen Inc. | Phase I | Recruiting | Oct 2024 | — |
IMP list
lock Showing 1 of 165 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 16 | Unknown | 2017-03-07 | 2026-05-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.